Exploring Glucagon-like peptide-1 as a Target Protein for Diabetes Mellitus Treatment: Molecular Docking and Pharmacokinetic Analysis of Phytocompounds from Momordica charantia

Year : 2024 | Volume : 02 | Issue : 01 | Page : 8-20
    By

    Dishant Chandgude,

  1. Student, BioNome for Genomics and Bioinformatics Solution, Bengaluru, Karnataka, India

Abstract

Objective: This study aimed to use molecular docking techniques to explore the potential of GLP-1 (glucagon-like peptide-1) as a target protein for the treatment of diabetes mellitus, a chronic metabolic disease marked by elevated blood glucose levels. Given its crucial role in maintaining insulin secretion and glucose homeostasis, GLP-1 may serve as a future target for diabetes therapy. Method: The study employed a multi-phase method. Initially, protein extraction was carried out using the Protein Data Bank ID 3C59 for GLP-1. The extracted structure was then verified through secondary structure prediction and Ramachandran Plot analysis to ensure its reliability. Phytocompounds from “Momordica charantia” were obtained using the IMPPAT Database. An ADME study was conducted to evaluate the pharmacokinetic characteristics of these compounds, including their absorption, distribution, metabolism, and excretion profiles. Molecular docking was then performed using PyRx to assess the binding affinity and interaction patterns between GLP-1 and the identified phytocompounds. The 3D and 2D interaction structures were subsequently examined using BIOVIA Discovery Studio to visualize the binding interactions and to identify key amino acid residues involved. Result: The molecular docking study identified diosgenin, alpha-spinasterol, and momordicoside I as potential drug candidates capable of modulating the activity of GLP-1. These compounds exhibited strong binding affinities and favorable interaction patterns with the GLP-1 protein. Conclusion: The study suggests that GLP-1 is a promising target for diabetes treatment, demonstrating favorable molecular interactions with phytocompounds derived from Momordica charantia. Structural validation and ADME analysis further support the potential efficacy of these compounds. These findings could lead to the development of new therapeutic approaches for managing diabetes, highlighting the significance of GLP-1 in diabetes therapy.

Keywords: GLP-1, diabetes treatment, molecular docking, Momordica charantia, phytocompounds, ADME analysis, structural validation

[This article belongs to International Journal of Biochemistry and Biomolecule Research ]

How to cite this article:
Dishant Chandgude. Exploring Glucagon-like peptide-1 as a Target Protein for Diabetes Mellitus Treatment: Molecular Docking and Pharmacokinetic Analysis of Phytocompounds from Momordica charantia. International Journal of Biochemistry and Biomolecule Research. 2024; 02(01):8-20.
How to cite this URL:
Dishant Chandgude. Exploring Glucagon-like peptide-1 as a Target Protein for Diabetes Mellitus Treatment: Molecular Docking and Pharmacokinetic Analysis of Phytocompounds from Momordica charantia. International Journal of Biochemistry and Biomolecule Research. 2024; 02(01):8-20. Available from: https://journals.stmjournals.com/ijbbr/article=2024/view=148032



Browse Figures

References

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care [online]. 2009;32(Suppl_1):S62–7. DOI: 10.2337/dc09-s062.
  2. Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol [online]. 2020;16(7):377–90. DOI: 10.1038/s41581-020-0278-5.
  3. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med [online]. 2013;159(8):543. DOI: 10.7326/0003-4819-159-8-201310150-00007.
  4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract [online]. 2018;138:271–81. DOI: 10.1016/j.diabres.2018.02.023.
  5. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol [online]. 2002;81(1):81–100. DOI: 10.1016/s0378-8741(02)00059-4.
  6. Richter E, Geetha T, Burnett D, Broderick TL, Babu JR. The effects of Momordica charantia on type 2 diabetes mellitus and Alzheimer’s disease. Int J Mol Sci [online]. 2023;24(5):4643. DOI: 10.3390/ijms24054643.
  7. Cortez-Navarrete M, Pérez-Rubio KG, Escobedo-Gutiérrez M de J. Role of Fenugreek, Cinnamon, Curcuma longa, Berberine, and Momordica charantia in type 2 diabetes mellitus treatment: A review. Pharmaceuticals (Basel) [online]. 2023;16(4):515. DOI: 10.3390/ph16040515.
  8. Dans AML, Villarruz MVC, Jimeno CA, Javelosa MAU, Chua J, Bautista R, et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol [online]. 2007;60(6):554–9. DOI: 10.1016/j.jclinepi.2006.07.009.
  9. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab [online]. 2018;27(4):740–56. DOI: 10.1016/j.cmet.2018.03.001
  10. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab [online]. 2021;46(101102):101102. DOI: 10.1016/j.molmet.2020.101102.
  11. Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides [online]. 2023;161(170939):170939. DOI: 10.1016/j.peptides.2023.170939.
  12. Muzurović EM, Volčanšek Š, Tomšić KZ, Janež A, Mikhailidis DP, Rizzo M, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease—current evidence. J Cardiovasc Pharmacol Ther [online]. 2022;27:107424842211463. DOI: 10.1177/10742484221146371.
  13. Klen J, Dolžan V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: The impact of pharmacological properties and genetic factors. Int J Mol Sci [online]. 2022;23(7):3451. DOI: 10.3390/ijms23073451
  14. RCSB Protein Data Bank. RCSB PDB: Homepage [online]. Rcsb.org. Available from: https://www.rcsb.org/
  15. Systèmes D. Free download: BIOVIA Discovery Studio Visualizer [online]. Dassault Systèmes. 2020. Available from: https://discover.3ds.com/discovery-studio-visualizer-download
  16. PROCHECK home page [online]. Ebi.ac.uk. Available from: https://www.ebi.ac.uk/thornton-srv/software/PROCHECK/
  17. PDBsum home page [online]. Ebi.ac.uk. Available from: https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/
  18. IMPPAT [online]. Res.in. Available from: https://cb.imsc.res.in/imppat/
  19. PubChem [online]. Nih.gov. Available from: https://pubchem.ncbi.nlm.nih.gov/
  20. SwissADME [online]. Swissadme.ch. Available from: http://www.swissadme.ch/
  21. Welcome to the PyRx website [online]. Sourceforge.io. Available from: https://pyrx.sourceforge.io/
Regular Issue Subscription Original Research
Volume 02
Issue 01
Received 15/05/2024
Accepted 27/05/2024
Published 28/05/2024
Publication Time 13 Days
Total Visits: 316


My IP

PlumX Metrics